Treatment of viral myocarditis with focus on captopril

American Journal of Cardiology

Volumn 77, Issue 8, 1996, Pages 634-637

  Rezkalla, Shereif H ^a   Raikar, Sharmishtha ^b   Kloner, Robert A ^b  

^a MARSHFIELD CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIVIRUS AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUNAZOSIN; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IBUPROFEN; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POLYCLONAL ANTIBODY; PREDNISONE; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; SALICYLATE SODIUM; VERAPAMIL;

ANIMAL MODEL; CARDIOVASCULAR INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COXSACKIE VIRUS; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; VIROGENESIS; VIRUS INFECTION; VIRUS MYOCARDITIS;

EID: 0029989601     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)89320-4     Document Type: Editorial

References (41)

1. Rezkalla S, Kloner RA. Management strategies in viral myocarditis. Am Heart J 1989;117:706-708.
2. Reid WD. The Heart in Modern Practice: Diagnosis and Treatment. Philadelphia: JB Lippincott, 1928:169.
3. 4. Observations over 12 months. Intervirology 1982;18:197-202.
4. Gwathmey JK, Nako S, Come PC, Goad MEP, Serur JR, Als AV, Abelmann WH. An experimental model of acute and subacute viral myocarditis in the pig. J Am Coll Cardiol 1992;19:864-869.
5. 4 virulence by indomethacin. J Lab Clin Med 1990;116:116-120.
6. 3 murine myocarditis. Deleterious effects of nonsteroidal anti-inflammatory agents. J Lab Clin Med 1986;107:393-395.
7. 3 murine myocarditis. J Am Coll Cardiol 1985;6:1078-1082.
8. Rezkalla S, Khatib R, Khatib G, Smith FE, Walsh M, Sowers J, Kloner R. Effect of indomethacin in the late phase of coxsackievirus myocarditis in a murine model. J Lab Clin Med 1988;112:118-121.
9. Matsumori A, Wang H, Abelmann WH, Crumpacker CS. Treatment of viral myocarditis with ribavirin in an animal preparation. Circulation 1985;71:834-839.
10. 3 myocarditis with analyses of lymphocyte subsets. J Am Coll Cardiol 1988;12:1334-1341.
11. 3-induced myocarditis with WIN 54954 in different formulations. Scand J Infect Dis 1993;88:125-130.
12. Ray CG, Icenogle TB, Minnich LL, Copeland JG, Grogan TM. The use of intravenous ribavirin to treat influenza virus-associated acute myocarditis. J Infect Dis 1989;159:829-836.
13. 3 myocarditis in mice. Am Hearf J 1988;115:1229-1232.
14. Matsumori A, Crumpacker CS, Abelmann WH. Prevention of viral myocarditis with recombinant human leucocyte interferon-α A/D in a murine model. J Am Coll Cardiol 1987;9:1320-1325.
15. 3 viral myocarditis and associated lymphoid organ atrophy with recombinant human leucocyte interferon-α A/D. Cardiovasc Res 1988;22:732-738.
16. Weller AH, Hall M, Huber SA. Polyclonal immunoglobulin therapy protects against cardiac damage in experimental coxsackievirus-induced myocarditis. Eur Heart J 1992;13:115-119.
17. O'Connell JB, Robinson JA, Henkin RE, Gunnar RM. Immunosuppressive therapy in patients with congestive cardiomyopathy and myocardial uptake of gallium-67. Circulation 1981;64:780-786.
18. Fenoglio JJ Jr, Ursell PC, Kellogg CF, Drusin RE, Weiss MB. Diagnosis and classification of myocarditis by endomyocardial biopsy. N Engl J Med 1983;308:12-18.
19. Daly K, Richardson PJ, Olsen EGJ, Morgan-Capner P, McSorley C, Jackson G, Jewitt DE. Acute myocarditis: role of histologic and virologic examination in the diagnosis and assessment of immunosuppressive treatment. Br Heart J 1984;51:30-39.
20. 3 myocarditis. Circulation 1986;73:353-359.
21. Tomioka N, Kishimoto C, Matsumori A, Kawai C. Effects of prednisolone on acute viral myocarditis in mice. J Am Coll Cardiol 1986;7:868-872.
22. Monrad ES, Matsumori A, Murphy JC, Fox JG, Crumpacker CS, Abelmann WH. Therapy with cyclosporin in experimental murine myocarditis with encephalomyocarditis virus. Circulation 1986;73:1058-1064.
23. 3 myocarditis. J Pharmacol Exp Ther 1991;260:1386-1391.
24. 3 myocarditis in mice by lobenzarit disodium through inhibition of splenic pan T cells. Cardiovasc Res 1993;27:243-248.
25. Maisch B, Schönian U, Hengstenberg C, Herzum M, Hufnagel G, Bethge C, Bittinger A, Neumann K. Immunosuppressive treatment in autoreactive myocarditis results from a controlled trial. Postgrad Med J 1994;70:529-834.
26. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE, and the Myocarditis Treatment Trial Investigators. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995;333:269-275.
27. 3 murine myocarditis. J Am Coll Cardiol 1988;12:412-414.
28. 1-blocker, bunazosin on a murine model of congestive heart failure induced by viral myocarditis. Jpn Circ J 1992;56:1138-1145.
29. Dong R, Liu P, Wee L, Butany J, Sole MJ. Verapamil ameliorates the clinical and pathological course of murine myocarditis. J Clin Invest 1992;90:2022-2030.
30. Chatterjee K, Parmley WW, Cohn JN, Levine TB, Awan NA, Mason DT, Faxon DP, Creager M, Gavras HP, Fouad FM, for The Captopril Multicenter Research Group I. A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response. Am Heart J 1985;110:439-447.
31. 3 murine myocarditis. Circulation 1990;81:1039-1046.
32. Rezkalla S, Kloner RA, Khatib G, Khatib R. Effect of delayed captopril therapy on left ventricular mass and myonecrosis during acute coxsackievirus murine myocarditis. Am Heart J 1990;120:1377-1381.
33. Suzuki H, Matsumori A. Myocardial injury due to viral myocarditis improved by captopril in mice (abstr). Circulation 1990;82(suppl III):III-674.
34. Suzuki H, Matsumori A, Kawai CH. Effects of angiotensin converting enzyme inhibitors on myocardial injury and congestive heart failure due to myocarditis in mice: comparison with captopril and enalapril. Circulation 1991;84(suppl II):III-634.
35. Agostoni PG, DeCesare N, Doria E, Polese A, Tamborini G, Guazzi MD. Afterload reduction: a comparison of captopril and nifedipine and dilated cardiomyopathy. Br Heart J 1986;55:391-399.
36. Khairallah PA, Robertson AL, Davilla D. Effects of angiotensin II on DNA, RNA, and protein synthesis. In: Genest J, Loiw E, eds. Hypertension. New York: Springer-Verlag, 1972:212-220.
37. Tanaka A, Matsumori A, Wang W, Sasayama S. An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis. Circulation 1994;90:2051-2055.
38. Westline W, Mullane K. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals? Circulation 1988;77(suppl I):I-30-I-39.
39. 3 myocarditis in mice. Cardiovasc Res 1992;26:956-961.
40. 3 myocarditis in mice. Cardiovasc Res 1993;27:957-961.
41. Suzuki H, Matsumori A, Matoba Y, Kyu BS, Tanaka A, Fujita J, Sasayama S. Enhanced expression of superoxide dismutase messenger RNA in viral myocarditis. J Clin Invest 1993;91:2727-2733.